Haploidentical hematopoietic stem cell transplantation as a first-line treatment for paediatric severe aplastic anemia: a single-center research
International Journal of Medical Sciences · 2024
DOI: 10.7150/ijms.94012 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Medical Sciences, 2024. Verfasst von Meng Yuan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics (Capital Medical University); Key L…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Anemia, Aplastic, Transplantation, Haploidentical. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
MRD-HSCT is the first-line therapy for children with SAA, while it is not easy to find a compatible donor due to the Chinese one-child policy. IST has a high recurrence rate, a risk of clonal transformation. Thus, Haplo-HSCT, as a first-line treatment, has gradually attracted clinicians' attention. To evaluate the efficacy of Haplo-HSCT in children with SAA, we performed a retrospective study (2006.06-2021.01) of 210 patients with AA who received HSCT or IST in Beijing Children's Hospital. The OS and FFS rates were analyzed to evaluate the efficacy of Haplo-HSCT and IST. We found that from 2006 to 2021, 3- and 5-year cumulative survival rates were both 85.3% in the first-line Haplo group, 98.1% and 96.8% in the first-line IST group, both 85.7% in the ATG group (P = 0.866), both 100% in the ATG + TPO group (P = 0.016), and 99.1% and 97.2% in the ATG + eltrombopag group (P = 0.056). 3- and 5-year cumulative FFS rates were both 85.3% in the first-line Haplo-HSCT group and 67.5% and 66.2% in the first-line IST group (P = 0.033). Therefore, we believe that Haplo-HSCT can be a first-line treatment for paediatric SAA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics (Capital Medical University); Key Laboratory of Major Diseases in Children, Ministry of Education; Beijin…
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zitieren
APA
Yuan, M., Jia, C., Ma, J., Zhang, M., Zhu, G., Wang, B., Zheng, J., Qin, M., Wu, R., & Li, S. (2024). Haploidentical hematopoietic stem cell transplantation as a first-line treatment for paediatric severe aplastic anemia: a single-center research. International Journal of Medical Sciences. https://doi.org/10.7150/ijms.94012
Vancouver
Yuan M, Jia C, Ma J, Zhang M, Zhu G, Wang B, et al. Haploidentical hematopoietic stem cell transplantation as a first-line treatment for paediatric severe aplastic anemia: a single-center research. International Journal of Medical Sciences. 2024. doi:10.7150/ijms.94012
BibTeX
@article{Yuan2024,
author = {Yuan, Meng and Jia, Chenguang and Ma, Jie and Zhang, Man and Zhu, Guanghua and Wang, Bin and Zheng, Jie and Qin, Maoquan and Wu, Runhui and Li, Sidan},
title = {Haploidentical hematopoietic stem cell transplantation as a first-line treatment for paediatric severe aplastic anemia: a single-center research},
journal = {International Journal of Medical Sciences},
year = {2024},
doi = {10.7150/ijms.94012}
}
EUVIMED